Baseret på data fra andre CYP3A4- hæmmere forventes plasmakoncentrationerne af midazolam at være signifikant højere, når midazolam gives oralt.
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally.